• Je něco špatně v tomto záznamu ?

Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness

I. Procházková, J. Lenčo, P. Bouchal,

. 2018 ; 1788 (-) : 177-184.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012995

Breast cancer is the most common and molecularly well-characterized malignant cancer in women; however, its progression to metastatic cancer remains lethal for 78% of patients within 5 years of diagnosis. Identifying novel markers in high risk patients using quantitative methods is essential to overcome genetic, inter-tumor, and intra-tumor variability, and to translate novel findings into cancer diagnosis and treatment. Using untargeted proteomics, we recently identified 13 proteins associated with some key factors of breast cancer aggressiveness: estrogen receptors, tumor grade, and lymph node status. Here we verified these findings in a set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM). This study highlights a panel of gene products that could contribute to breast cancer aggressiveness and metastasis, and can help develop more precise breast cancer treatments.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012995
003      
CZ-PrNML
005      
20190412120751.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/7651_2017_111 $2 doi
035    __
$a (PubMed)29196895
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Procházková, Iva $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic. Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology, Brno, Czech Republic.
245    10
$a Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness / $c I. Procházková, J. Lenčo, P. Bouchal,
520    9_
$a Breast cancer is the most common and molecularly well-characterized malignant cancer in women; however, its progression to metastatic cancer remains lethal for 78% of patients within 5 years of diagnosis. Identifying novel markers in high risk patients using quantitative methods is essential to overcome genetic, inter-tumor, and intra-tumor variability, and to translate novel findings into cancer diagnosis and treatment. Using untargeted proteomics, we recently identified 13 proteins associated with some key factors of breast cancer aggressiveness: estrogen receptors, tumor grade, and lymph node status. Here we verified these findings in a set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM). This study highlights a panel of gene products that could contribute to breast cancer aggressiveness and metastasis, and can help develop more precise breast cancer treatments.
650    _2
$a nádorové biomarkery $x analýza $7 D014408
650    _2
$a prsy $x patologie $7 D001940
650    _2
$a nádory prsu $x diagnóza $x patologie $7 D001943
650    _2
$a chromatografie iontoměničová $x metody $7 D002852
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hmotnostní spektrometrie $x metody $7 D013058
650    _2
$a proteom $x analýza $7 D020543
650    _2
$a proteomika $x metody $7 D040901
650    _2
$a odběr biologického vzorku $x metody $7 D013048
650    _2
$a barvení a značení $x metody $7 D013194
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lenčo, Juraj $u Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.
700    1_
$a Bouchal, Pavel $u Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic. bouchal@chemi.muni.cz.
773    0_
$w MED00180389 $t Methods in molecular biology (Clifton, N.J.) $x 1940-6029 $g Roč. 1788, č. - (2018), s. 177-184
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29196895 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190412120809 $b ABA008
999    __
$a ok $b bmc $g 1392305 $s 1051300
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 1788 $c - $d 177-184 $i 1940-6029 $m Methods in molecular biology $n Methods Mol Biol $x MED00180389
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace